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ABSTRACT 
Introduction: HIV incidence estimates are critical for monitoring HIV transmission dynamics, and for 
design and evaluation of the impact of interventions. Biomarkers and assays for cross-sectional 
surveillance of HIV incidence are greatly needed because of the high costs and time needed to 
maintain prospective cohorts to determine HIV incidence. New cross-sectional assays for estimation of 
HIV incidence are attractive due to their improved performance and cost-effectiveness. In this 
dissertation, methods for identification and characterization of recency of HIV infection are described. 
An in-depth review of HIV recency determination methods, including novel cross-sectional application 
of molecular methods, is given in “From serological assays to genomics.” Multi-assay approaches 
were evaluated in order to increase the sensitivity and specificity of the commercial incidence assays in 
the context of high treatment coverage and stable but high HIV prevalence in Botswana. A novel 
biomarker based on HIV viral diversity was investigated as a complementary or standalone tool to 
characterize HIV recency. In this thesis, an innovative use of pairwise diversity and the time to the 
most recent common ancestor (tMRCA) in a heterosexual HIV-1 subtype C (HIV-1C) epidemic were 
introduced as novel approaches for HIV incidence estimation.  We evaluated the properties of the new 
potential tools for estimating time since infection, including their specificity and predictive 
performance in the context of the HIV-1C epidemic in Botswana. 
Methods: Characterization of HIV recency and novel biomarkers for estimation of HIV infection 
incidence is based on application of immunologic and molecular methods:  
a) Evaluation of the long-term specificity (false recent classification rates) of serological tests for
recent infection, and algorithms for estimating HIV-1C incidence utilizing samples from
patients with known long-standing HIV infection.
b) Application of within-host viral diversity for estimation of HIV-1C recency in Botswana using
samples collected from patients with known time since seroconversion in the primary HIV-1C
infection cohort.
c) Investigation of intra-host viral pairwise diversity and the time to the most common recent
ancestor (tMRCA), as potential markers for HIV infection recency.
Results: We estimated for the first time false recency rates (FRR) of the commercially available BED 
and Limiting Antigen (LAg) assays in Botswana. We demonstrated that combined algorithms reduce 
FRR to the recommended < 2%. Including viral load in the assay algorithm resulted in an FRR of 0.4% 
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for LAg. Analysis of the within-host viral pairwise diversity provided more accurate estimation of HIV 
recency, as compared with the recommended LAg and BED using the receiver operator characteristic 
analysis (ROC). We demonstrated that intra-host viral pairwise distances reduce misclassification and 
increase the accuracy of serologic assays. tMRCA and intra-host viral pairwise distances correlated 
with time since HIV infection provide additional novel tools for reliable estimation of HIV recency.   
Conclusion: HIV infection recency can be determined cross-sectionally using a combination of 
serological and molecular biomarkers.  Including viral load and an assessment of prior exposure to 
ARVs is critical for accurate estimation of HIV incidence. Intra-host pairwise diversity and tMRCA 
are able to predict time since HIV infection and can be used to improve accuracy in estimation of HIV 
infection recency.  
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OPSOMMING (AFRIKAANS) 
Inleiding: MIV voorkoms skattings is van kritieke belang vir die monitering van MIV-oordrag 
dinamika, en vir die ontwerp en evaluering van die impak van intervensies. Biomerkers en toetse vir 
deursnee-toesig van MIV voorkoms is baie nodig as gevolg van die hoë koste en tyd wat nodig is om 
voornemende kohorte in stand te hou om MIV voorkoms te bepaal. Nuwe deursnee-toetse vir skatting 
van MIV voorkoms is aantreklik as gevolg van hul verbeterde prestasie en koste-effektiwiteit. In 
hierdie verhandeling word metodes vir die identifikasie en karakterisering van resentheid van MIV-
infeksie beskryf. 'N In-diepte oorsig van MIV relevante bepaling metodes, insluitend roman deursnee-
toepassing van molekulêre metodes, word in "Van serologiese toetse om genomika." Multi-toets 
benaderings is om die sensitiwiteit en spesifisiteit van die kommersiële voorkoms verhoog geëvalueer 
toetse in die konteks van 'n hoë dekking behandeling en stabiele maar 'n hoë voorkoms van MIV in 
Botswana. 'N roman biomerker wat gebaseer is op MIV virale diversiteit ondersoek as 'n aanvullende 
of selfstandige instrument om MIV relevante kenmerk. In hierdie tesis, 'n innoverende gebruik van 
paarsgewyse diversiteit en die tyd om die mees onlangse gemeenskaplike voorouer (tMRCA) in 'n 
heteroseksuele MIV-1 subtipe C (HIV-1 C) epidemie is ingestel as nuwe benaderings vir MIV 
voorkoms skatting. Ons geëvalueer die eienskappe van die nuwe potensiële gereedskap vir die 
beraming keer sedert infeksie, insluitend hul spesifisiteit en voorspellende prestasie in die konteks van 
die MIV-1C epidemie in Botswana. 
. 
Metodes: Karakterisering van MIV relevante en nuwe biomerkers vir skatting van MIV-infeksie 
voorkoms is gebaseer op die toepassing van immunologiese en molekulêre metodes:  
a) Evaluering van die langtermyn-spesifisiteit (valse onlangse klassifikasie tariewe) van serologiese
toetse vir onlangse infeksie, en algoritmes vir die beraming van MIV-1C voorkoms met behulp van die 
monsters van pasiënte met 'n bekende lang MIV-infeksie.  
b) Toepassing van binne-gasheer virale diversiteit vir skatting van MIV-1C resentheid in Botswana
met behulp van monsters van pasiënte met 'n bekende keer sedert sero Omskakeling geconstateerd in 
die primêre MIV-1C infeksie vorder.  
c) Ondersoek van intra-gasheer virale paarsgewyse diversiteit en die tyd om die mees algemene
onlangse voorouer (tMRCA), as 'n potensiële merkers vir MIV-infeksie resentheid.  
Resultate: Ons beraam vir die eerste keer valse relevante tariewe (FRR) van die kommersieel 
beskikbare BED en beperking van Antigeen (lag) toetse in Botswana. Ons het getoon dat 
gekombineerde algoritmes te verminder FRR om die aanbevole <2%. Insluitend virale lading in die 
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toets algoritme tot gevolg gehad dat 'n FRR van 0,4% vir lag. Ontleding van die binne-gasheer virale 
paarsgewyse diversiteit verskaf meer akkurate skatting van MIV resentheid, in vergelyking met die 
aanbevole lag en 'n bed met behulp van die ontvanger operateur eienskap analise (ROC). Ons het 
getoon dat intra-gasheer virale paarsgewyse afstande te verminder foutieve classificatie en verhoog die 
akkuraatheid van serologic toetse. tMRCA en intra-gasheer virale paarsgewyse afstande gekorreleer 
met die tyd sedert MIV-infeksie bykomende roman gereedskap vir 'n betroubare beraming van MIV 
resentheid.   
Gevolgtrekking: MIV-infeksie resentheid kan kruis-sectionally bepaal met behulp van 'n kombinasie 
van serologiese en molekulêre biomerkers. Insluitend virale lading en 'n evaluering van vorige 
blootstelling aan ARV is van kritieke belang vir akkurate skatting van MIV voorkoms. Intra-gasheer 
paarsgewyse diversiteit en tMRCA in staat is om tyd te voorspel, aangesien MIV-infeksie en kan 
gebruik word om die akkuraatheid in raming van MIV-infeksie relevante verbeter. 
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CHAPTER 1 
INTRODUCTION 
 
1.1 The HIV Epidemic in Botswana  
Thirty years into the global Human Immunodeficiency Virus (HIV) pandemic, HIV 
prevalence and incidence remain high in sub-Saharan Africa, with 25.6 million people living 
with HIV as of the end of 2015 (1). Although sub-Saharan Africa represents only 12% of the 
world’s population, it accounts for approximately 67% of the world’s 36.7 million HIV-
infected persons, and about two-thirds of the world’s 2.1 million new infections occur in this 
region annually (1).  
 
Botswana, a politically stable country in southern Africa, has experienced an explosive and 
devastating HIV epidemic since the first case was identified in 1985 (2). HIV prevalence 
among antenatal clinic attendees increased from 6% in the early 1990s to 36% in 2002 (2). 
The Sentinel Surveillance surveys conducted over 14 years in Botswana revealed an overall 
decline in HIV prevalence among pregnant women although this remains above 30% (3-6). 
General population-based surveys conducted approximately every four years have shown 
evidence of decline in new HIV infections and stabilisation of HIV prevalence among adults 
aged 15–49 years and decline in HIV prevalence among the younger age groups (7, 8). Key 
populations such as female sex workers (FSW) have prevalence rates of over 60% (9). 
 
In response to the epidemic, Botswana has been one of the leaders in adopting and 
implementing HIV prevention and treatment interventions. In January 2002 Botswana 
officially initiated a national antiretroviral treatment (ART) program providing highly active 
antiretroviral therapy (HAART) to its citizens. To date, over 86% of HIV-infected 
individuals in Botswana are receiving ART (10), and all public health facilities provide ARV 
for the prevention of mother-to-child transmission (PMTCT) services, resulting in one of the 
lowest MTCT rates globally (<1.5%) (11, 12). 
 
In 2014, the Joint United Nations Programme on HIV/AIDS (UNAIDS) proposed new targets 
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directed at ending the AIDS epidemic by 2030 (13). Namely, by 2020, 90% of all people 
living with HIV should know their HIV status; 90% of all people with diagnosed HIV 
infection should receive sustained combination ART; and 90% of all people receiving ART 
should be virologically suppressed. Owing to the substantial progress made in providing HIV 
treatment and prevention of MTCT services to its citizens, Botswana is one of the few 
countries worldwide to be close to meeting these targets (10). However, with an estimated 
24% of its adult residents (aged 15–49) HIV-infected, Botswana has one of highest adult HIV 
prevalence and the third highest national HIV incidence rate globally (1, 7, 14, 15).  
Appropriate tools are therefore required for monitoring HIV incidence in Botswana and for 
evaluating the impact of the public health response as well as identifying the drivers of the 
high HIV incidence, both in the general population and in special key populations.  
 
1.2 The Challenge of Estimation of HIV Incidence 
The ability to accurately estimate incidence, or the risk of acquiring infection within a given 
period of time is an essential component of monitoring  the transmission dynamics of HIV 
(16-22) and evaluate prevention efforts,  especially in the era of broad scale-up of ART and 
universal test and treatment (20, 23).  Accurate surveillance of recently infected individuals 
and estimation of HIV incidence can also inform the design and evaluation of intervention 
strategies (24), and assist in the design of efficacy clinical studies and identify high risk sub-
groups. Treatment as prevention (TasP) is likely to be more cost effective if individuals in the early 
infection phase, responsible for disproportionately higher rates of onward transmission, are a primary 
focus(25-29). 
 
Estimating HIV incidence remains challenging despite the development of several methods 
(30).  A classical approach to estimating HIV incidence is based on longitudinal follow-up of 
uninfected individuals (31-33). However, this approach is expensive, time consuming and 
logistically challenging to implement (24). Other approaches include the use of mathematical 
models such as back-calculation methods that infer incidence from changes in prevalence in 
serial surveys (34). The development of cross-sectional assays relies on the evolution of the 
host’s immune responses, or use of viral markers (30, 35-37). The main concept behind the 
cross-sectional approach is based on a specific biological marker (biomarker) associated with 
changes in the host’s immune response to HIV infection, and able to distinguish recent from 
established (long-term, or chronic) HIV infections (35, 38-40).  
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In Chapter 2, a detailed description of these methods is provided  
 
 
1.3 Study rationale  
Despite the development of cross sectional methods to identify recent infections and estimate 
HIV incidence, so far no method or biomarker has sufficient properties to provide robust 
estimations of HIV incidence.  New biomarkers and assays for cross-sectional surveillance of 
HIV incidence are needed as an alternative to the prospective cohorts that are costly and time 
consuming. Serological tests can also be used cross-sectionally for estimation of recent HIV 
infections due to improved performance of new assays and their associated algorithms (41). 
However, these assays can misclassify some long-term infected individuals as recent cases 
(42). Their specificity is affected by exposure to ART, co-infections, HIV-1 subtype, and 
long-term non-progressors and viremic controllers (37, 43-45). The false recency rate 
(specificity) needs to be taken into account in order to improve the utility of these assays (46, 
47). To my knowledge there has not been any studies evaluating specificity of the cross 
sectional incidence assays in Botswana. I also tested the hypothesis that multi-assay 
algorithms are likely to increase specificity of the serological assays that previously 
demonstrated non-subtype C HIV-1 infections. Viral diversity-based assays are receiving 
increasing attention as complementary or new alternatives to immunoassays (38, 48-53) but 
there is limited data on how accurately these could be applied to characterize HIV recency.  
 
 
In this dissertation, I assessed the incidence assays and multi-assay approaches to maximise 
their sensitivity and specificity in the context of high ART coverage and high HIV-1C 
prevalence in Botswana.  I examined whether a novel biomarker based on HIV viral diversity 
can be used to characterize recency of HIV infection. In this thesis an innovative use of 
pairwise diversity and the time to the most recent common ancestor (tMRCA) in a 
heterosexual HIV-1C epidemic are explored as potential approaches for identifying recent 
infections.  I further analyzed the properties of the new tools including their specificity and 
predictive performance in the context of the HIV-1C epidemic in Botswana. The thesis is 
organized in the form of manuscripts to address 3 specific aims. 
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1.4 Specific Aims 
Aim 1: To identify and characterize early founder viruses using cross sectional serological 
markers. 
Aim 2: To determine if virus genomic variation (pairwise diversity) can be used to determine 
recency of HIV infection 
Aim 3: To determine if coalescence models can be used to estimate the time since HIV 
infection  
 
 
1.5 Summary of enclosed publications 
In Chapter 2, I describe the methods for identifying recent infection using an in-depth review 
of literature covering serological assays that measure changes in the immune response, 
application of genomics in the form of diversity based assays and standard application of 
mathematical models. The paper examines the successes and challenges in application of 
these methods in surveillance and research, and identifies opportunities for further 
development.  The traditional approach of following HIV negative cohorts is logically 
complex, very expensive and may be subject to biases related to following up individuals 
over long periods. The cross-sectional approaches are therefore the most appealing but 
require evaluation, characterization and optimization in each local context.  
 
The drawback of serological assays includes the variability across subtypes, long-term non-
progressors, impact of exposure to ART, impact of HIV-1 viral load and co-infections. In 
chapters 3 and 4, I examined the strategies for improving the specificity of the cross-sectional 
assays using multi-assay algorithms.  
 
In the papers enclosed in chapter 5 and 6, I describe the novel use of viral diversity to 
determine HIV recency of infection using pairwise distances or time to the most common 
recent ancestor (tMRCA). Viral diversity based assays are potential alternatives or 
complementary methodologies to immunoassays.  Since intra-host diversity increases linearly 
within hosts from early to chronic phases of infection, I determined if it can be applied in 
determining HIV recency using a unique set of samples with known estimated time since 
infection.   
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1.6 Manuscripts enclosed in this thesis  
 
The following papers are enclosed as part of this thesis: 
 
Chapter 2 – Identifying Recent HIV infections: From Serological Assays to Genomics 
 
Paper 1: Moyo, S., E. Wilkinson, V. Novitsky, A. Vandormael, S. Gaseitsiwe, 
M. Essex, S. Engelbrecht and T. de Oliveira (2015). Identifying Recent HIV 
Infections: From Serological Assays to Genomics. Viruses 7(10): 5508-5524. 
 
  Number of citations by 01 Aug 2016 = 3 citations 
 
Chapter 3 – Improved cross-sectional estimate of HIV-1 subtype C incidence using 
multi-assay algorithms 
 
Paper 2: Moyo, S., T. LeCuyer, R. Wang, S. Gaseitsiwe, J. Weng, R. 
Musonda, H. Bussmann, M. Mine, S. Engelbrecht, J. Makhema, R. Marlink, 
M. K. Baum, V. Novitsky and M. Essex (2014). "Evaluation of the false 
recent classification rates of multiassay algorithms in estimating HIV type 1 
subtype C incidence." AIDS Res Hum Retroviruses 30(1): 29-36. 
 
Number of citations by 01 Aug 2016 = 6 citations 
 
Paper 3: Wang, R., J. Weng, S. Moyo, D. Pain, C. D. Barr, D. Maruapula, D. 
Mongwato, J. Makhema, V. Novitsky and M. Essex (2013). Short 
communication: effect of short-course antenatal zidovudine and single-dose 
nevirapine on the BED capture enzyme immunoassay levels in HIV type 1 
subtype C infection. AIDS Res Hum Retroviruses 29(6): 901-906. 
 
Paper 4: Sikhulile Moyo, Kenanao P Kotokwe, Terence Mohammed,, 
Corettah Boleo, Lucy Mupfumi,, Samuel Chishala, Lesedi Tsalaile, Hermann 
Bussmann, Simani Gaseitsiwe, Rosemary Musonda, Joseph Makhema, 
Marianna Baum, Richard Marlink, Susan Engelbretch, M. Essex &Vladimir 
Novitsky. Low False Recent Rate of Limiting Antigen-Avidity Assay Combined 
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with HIV-1 RNA Data in Botswana. AIDS Res Hum Retroviruses 2016 Sep 7. 
[Epub ahead of print] 
 
 
Chapter 4 – Within-host pairwise diversity and recency of HIV infection 
 
Paper 5: Sikhulile Moyo, Alain Vandormael, Eduan Wilkinson, Susan 
Engelbrecht, Simani Gaseitsiwe, Kenanao P. Kotokwe, Rosemary Musonda , 
Frank Tanser , Max Essex , Vladimir Novitsky, Tulio de Oliveira. PLOS One 
(2016). Analysis of viral diversity in relation to the recency of HIV-1C 
infection in Botswana – PLoS One. 2016 Aug 23;11(8):e0160649. 
 
 
Chapter 5 – Evolutionary dynamics in primary HIV-1C infection 
 
Paper 6: Sikhulile Moyo, Eduan Wilkinson, Alain Vandormael, Rui Wang, 
Jia Weng, Kenanao P. Kotokwe, Simani Gaseitsiwe, Rosemary Musonda, 
Joseph Makhema, M. Essex, Susan Engelbrecht, Tulio de Oliveira, and 
Vladimir Novitsky. Pairwise Diversity and tMRCA as Potential Markers for 
HIV Infection Recency. MEDICINE (Submitted – Under Review) 
 
Chapter 6 - Summative Comment 
 
 
Chapter 7 – Additional Materials  
 
Conference Abstracts related to the thematic areas 
 
1) Conference on Retrovirus and Opportunistic Infections (CROI 2016) 
Moyo, S et al., Cross-sectional HIV Incidence in 24 communities in Botswana. 
(Poster) 
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2) 21st International AIDS Society Conference (IAS July, AIDS2016) 
Moyo, S et al., Cross-sectional estimates of HIV incidence remain high in rural 
communities in Botswana in the era of successful scale-up of ART. (Oral 
Poster) 
3) Viral Evolution and Molecular Epidemiology (VEME, Aug 2016) 
Moyo, S et al., Pairwise Diversity and tMRCA as potential markers for HIV 
Infection Recency. (Accepted, Poster) 
4) HIV Dynamics and Evolution (April 2016) 
Moyo, S et al., Analysis of viral diversity in relation to the recency of HIV-1C 
infection in Botswana. (Accepted Poster) 
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CHAPTER 2 
IDENTIFYING RECENT HIV INFECTIONS:  FROM SEROLOGICAL 
ASSAYS TO GENOMICS 
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About this article 
 
Paper 1: Identifying Recent HIV Infections: From Serological Assays to Genomics 
Moyo, S., E. Wilkinson, V. Novitsky, A. Vandormael, S. Gaseitsiwe, M. Essex, S. 
Engelbrecht and T. de Oliveira (2015). "Identifying Recent HIV Infections: From Serological 
Assays to Genomics." Viruses 7(10): 5508-5524. 
 
 
Abstract: In this paper, we review serological and molecular based methods to identify 
HIV infection recency. The accurate identification of recent HIV infection continues to 
be an important research area and has implications for HIV prevention and treatment 
interventions. Longitudinal cohorts that follow HIV negative individuals over time are 
the current gold standard approach, but they are logistically challenging, time 
consuming and an expensive enterprise. Methods that utilize cross-sectional testing and 
biomarker information have become an affordable alternative to the longitudinal 
approach. These methods use well-characterized biological makers to differentiate 
between recent and established HIV infections. However, recent results have identified 
a number of limitations in serological based assays that are sensitive to the variability in 
immune responses modulated by HIV subtypes, viral load and antiretroviral therapy. 
Molecular methods that explore the dynamics between the timing of infection and viral 
evolution are now emerging as a promising approach. The combination of serological 
and molecular methods may provide a good solution to identify recent HIV infection in 
cross-sectional data. As part of this review, we present the advantages and limitations 
of serological and molecular based methods and their potential complementary role for 
the identification of HIV infection recency. 
Keywords: recent HIV infection; viral diversity; serology-based assays, molecular-
based assays 
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CHAPTER 3 
IMPROVED CROSS-SECTIONAL ESTIMATE OF HIV-1 SUBTYPE C 
INCIDENCE USING MULTI-ASSAY ALGORITHMS 
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Paper 2: Evaluation of the false recent classification rates of multiassay 
algorithms in estimating HIV type 1 subtype C incidence 
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About this article 
 
 
Moyo, S., T. LeCuyer, R. Wang, S. Gaseitsiwe, J. Weng, R. Musonda, H. Bussmann, M. 
Mine, S. Engelbrecht, J. Makhema, R. Marlink, M. K. Baum, V. Novitsky and M. Essex 
(2014). "Evaluation of the false recent classification rates of multiassay algorithms in 
estimating HIV type 1 subtype C incidence." AIDS Res Hum Retroviruses 30(1): 29-36. 
 
Summary 
Laboratory cross-sectional assays are useful for estimation of HIV incidence, but are known 
to misclassify individuals with long-standing infection as recently infected. The false recent 
rate (FRR) varies widely across geographic areas; therefore, accurate estimates of HIV 
incidence require a locally defined FRR. We determined FRR for Botswana, where HIV-1 
subtype C infection is predominant, using the BED capture enzyme immunoassay (BED), a 
BioRad Avidity Index (BAI) assay (a modification of the BioRad HIV1/2+O EIA), and two 
multi-assay algorithms (MAA) that included clinical data. To estimate FRR, stored blood 
samples from 512 antiretroviral (ARV)-naïve HIV-1 subtype C-infected individuals from a 
prospective cohort in Botswana were tested at 18–24 months post-enrolment.  The following 
FRR mean (95% CI) values were obtained: BED 6.05% (4.15–8.48), BAI 5.57% (3.70–8.0), 
BED-BAI 2.25% (1.13–4.0), and a combination of BED-BAI with CD4 (>200) and viral load 
(>400) threshold 1.43% (0.58–2.93). The inter-assay agreement between BED and BAI was 
92.8% (95%CI, 90.1–94.5) for recent/long-term classification. Misclassification was 
associated with viral suppression for BED [adjusted OR (aOR) 10.31; p = 0.008 )], BAI [aOR 
9.72; p =0.019 ] and MAA1 [aOR 16.6 ; p = 0.006].Employing MAA can reduce FRR to < 
2%. A local FRR can improve cross-sectional HIV incidence estimates. 
 
Key words: HIV-1 Subtype C, False Recent Rate HIV Incidence, Botswana, BED, Avidity 
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Paper 3: Effect of short-course antenatal zidovudine and single-dose 
nevirapine on the BED capture enzyme immunoassay levels in HIV type 1 
subtype C infection 
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Wang, R., J. Weng, S. Moyo, D. Pain, C. D. Barr, D. Maruapula, D. Mongwato, J. Makhema, V. 
Novitsky and M. Essex (2013). "Short communication: effect of short-course antenatal zidovudine 
and single-dose nevirapine on the BED capture enzyme immunoassay levels in HIV type 1 subtype C 
infection." AIDS Res Hum Retroviruses 29(6): 901-906. 
 
About this article 
Summary 
Cross-sectional prevalence studies based on immunoassays that discriminate between 
recent and long-term infections, such as the BED assay, have been widely used to estimate 
HIV incidence. However, individuals receiving highly active antiretroviral therapy tend to 
have lower BED levels and are associated with a higher risk for being mistakenly classified 
as recent infections. To assess the effect of short-term antenatal Zidovudine (ZDV) and 
single-dose Nevaripine (sdNVP) on the BED levels in HIV-1C infection, we measured 
longitudinal BED optical density (OD-n) levels using stored plasma samples collected pre- 
and post-natally from 159 pregnant HIV-infected women in Botswana who participated in the 
randomized clinical Mother-to-Child-Prevention study, the Mashi study. All women received 
ZDV from 34 weeks gestation through delivery and were randomized to receive either 
sdNVP or placebo during labor. Among 159 subjects, the OD-n levels decreased from 
baseline to delivery in 93 subjects (p=0.039), suggesting that short-course ZDV may decrease 
OD-n levels. sdNVP at delivery did not affect longitudinal BED OD-n levels post-delivery. 
However, sdNVP appeared to modify the association between CD4 count at delivery and 
OD-n levels post-delivery. When estimating HIV incidence with the BED assay, special care 
may be required regarding women who received short-term ZDV for prevention of mother-
to-child transmission.  
 
Key Words: BED, HIV incidence, mother-to-child transmission, Nevirapine, Zidovudine.
Stellenbosch University  https://scholar.sun.ac.za
  31 
  
Paper 4: Low False Recent Rate of Limiting Antigen-Avidity Assay 
Combined with HIV-1 RNA Data in Botswana  
 
 
 
 
 
The journal's copyright rules do not allow placing it for open access through SUNScholar. The 
PubMed link below links to the abstract, with access to full text available online depending on your 
institutions subscriptions. The summary of this paper is given below. 
 
To request an author copy reprint, contact the author at: sikhulilemoyo@gmail.com 
 
 
 
PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/27481530/ 
 
DOI: https://dx.doi.org/10.1089/AID.2016.0127 
 
 
 
 
 
 
 
Stellenbosch University  https://scholar.sun.ac.za
  32 
Sikhulile Moyo, Kenanao P Kotokwe, Terence Mohammed, Corettah Boleo, Lucy Mupfumi, 
Samuel Chishala, Lesedi Tsalaile, Hermann Bussmann, Simani Gaseitsiwe, Rosemary 
Musonda, Joseph Makhema, Marianna Baum, Richard Marlink, Susan Engelbretch, M. Essex 
&Vladimir Novitsky. Low False Recent Rate of Limiting Antigen-Avidity Assay Combined 
with HIV-1 RNA Data in Botswana. AIDS Res Hum Retroviruses 2016 Sep 7. [Epub ahead 
of print] 
 
 
 
About this article 
Summary 
Cross-sectional estimation of HIV incidence could misclassify some established or chronic 
HIV infections as recent. Usually long-term non-progressors, elite and viremic controllers, 
and individuals on ART contribute to misclassification. Local data on the false recent rate 
(FRR) could minimize misclassification during estimation of HIV incidence. To improve 
monitoring of HIV incidence, we estimated local FRR in Botswana. A total of 1036 
specimens from individuals infected for least 1.5 to 2 years were sampled between 2004 and 
2009, and tested using the Limiting Antigen-Avidity assay (LAg) using a cutoff of 1.5 
normalized optical density units (OD-n). The FRR was 0.97% (10/1036; 95% confidence 
interval (CI) 0.46–1.77). Four samples had HIV-1 RNA >1000 cps/mL, giving an adjusted 
FRR of 0.39% (4/1036; 95% CI 0.11–0.99). A combination of LAg and HIV-1 RNA load 
data resulted in FRR below 1% in the Botswana population. 
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CHAPTER 4 
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RECENCY OF HIV INFECTION 
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One. 2016 Aug 23;11(8):e0160649. 
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About this paper 
 
Summary 
 
Background: Cross-sectional, biomarker methods to determine HIV infection recency 
present a promising and cost-effective alternative to the repeated testing of uninfected 
individuals. We evaluate a viral-based assay that uses a measure of pairwise distances (PwD) 
to identify HIV infection recency, and compare its performance with two serologic incidence 
assays, BED and LAg. In addition, we assess whether combination BED plus PwD or LAg 
plus PwD screening can improve predictive accuracy by reducing the likelihood of a false-
recent result.     
Methods: The data comes from 854 time-points and 42 participants enrolled in a primary 
HIV-1C infection study in Botswana. Time points after treatment initiation or with evidence 
of multiplicity of infection were excluded from the final analysis. PwD was calculated from 
quasispecies generated using single genome amplification and sequencing. We evaluated the 
ability of PwD to correctly classify HIV infection recency within <130, <180 and <360 days 
post-seroconversion using Receiver Operator Characteristics (ROC) methods. Following a 
secondary PwD screening, we quantified the reduction in the relative false-recency rate 
(rFRR) of the BED and LAg assays while maintaining a sensitivity of either 75, 80, 85 or 
90%.   
Results: The final analytic sample consisted of 758 time-points from 40 participants. The 
PwD assay was more accurate in classifying infection recency for the 130 and 180-day cut-
offs when compared with the recommended LAg and BED thresholds. A higher AUC 
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statistic confirmed the superior predictive performance of the PwD assay for the three cut-
offs. When used for combination screening, the PwD assay reduced the rFRR of the LAg 
assay by 52% and the BED assay by 57.8% while maintaining a 90% sensitivity for the 130 
and 180-day cut-offs respectively.   
Conclusion: PwD can accurately determine HIV infection recency. A secondary PwD 
screening reduces misclassification and increases the accuracy of serologic-based assays.  
Abbreviations: PwD, pairwise diversity; BED, Calypte Incidence Assay; LAg, Limiting 
Antigen Assay; ROC, receiver operator characteristics; FRR, false-recency rate; ART, 
antiretroviral treatment; TPR, true positive rate; AUC, area under the curve. 
Keywords: HIV recency rate; False recency rate; Pairwise diversity; HIV1-C; BED; 
Limiting Antigen Assay; Botswana 
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CHAPTER 5 
EVOLUTIONARY DYNAMICS IN PRIMARY HIV-1C INFECTION 
 
One manuscript (unpublished) was submitted MEDICINE JOURNAL and is under review.  
The text format is as required by the respective journals where published 
 
Paper 6:  Pairwise Diversity and tMRCA as Potential Markers for HIV 
Infection Recency	
 
Sikhulile Moyo, Eduan Wilkinson, Alain Vandormael, Rui Wang, Jia Weng, Kenanao P. 
Kotokwe, Simani Gaseitsiwe, Rosemary Musonda, Joseph Makhema, M. Essex, Susan 
Engelbrecht, Tulio de Oliveira, and Vladimir Novitsky. MEDICINE (SUBMITTED - 
Underview) 
 
About this paper 
Summary 
Intra-host HIV-1 diversity increases linearly over time. We assessed the extent to which 
mean pairwise distances and the time to the most recent common ancestor (tMRCA) inferred 
from intra-host HIV-1C env sequences are associated with the estimated time of HIV 
infection. Data from a cohort of 42 participants with estimated time of seroconversion from 
the primary HIV-1C infection study in Botswana were used in this analysis. A total of 2,540 
HIV-1C env gp120 V1C5 viral sequences were generated by single genome amplification 
and sequencing, an average of 61 sequences per participant and 11 per time point per 
participant. Raw pairwise distances were calculated per time point per patient using the ape 
package in R. The tMRCA was estimated per time per patient using phylogenetic inference 
implemented in BEAST v1.8.2. Pairwise distances and tMRCA were significantly associated 
with the estimated time since HIV infection (both p < 0.001), and taking into account 
multiplicity of HIV infection strengthened these associations. HIV-1C env-based pairwise 
distances and tMRCA can be used as potential markers for HIV recency. However, the 
estimated tMRCA demonstrated no advantage over pairwise distances.  
  
 Keywords: tMRCA, pairwise distances, HIV recency, HIV incidence, HIV-1C.   
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CHAPTER 6   
GENERAL DISCUSSION AND CONCLUSIONS 
 
The publications included in this dissertation focused on the characterization of recency of 
HIV infection and the exploration of novel biomarkers for estimation of HIV incidence based 
on application of immunologic and molecular methods in the context of a HIV-1 subtype C 
epidemic in southern Africa. These studies could guide and set priorities for further 
population-based studies addressing cross-sectional HIV incidence, and to design and 
monitor interventions that aim to reduce and eliminate new HIV infections [1-3]. Although 
progress has been made in development and validation of cross-sectional tests for recent HIV 
infection (TRI), new biomarkers and improved algorithms are required.  
 
Research included in the thesis demonstrated that specificity of cross-sectional TRIs can be 
improved by algorithms that combine multiple assays, clinical data on disease progression 
(viral load/CD4), and viral diversity. To my knowledge, including viral load in a multi-assay 
algorithm (MAA) resulted in the one the lowest false recency rate of the Limiting Antigen 
Avidity assay ever reported (paper 4). This MAA was used for estimating cross-sectional 
HIV incidence in Botswana [14]. A novel biomarker based on HIV diversity was investigated 
as a potential tool for characterizing recency of HIV infection and inferring time since 
infection. This work has major implications for tracking newly transmitted HIV infections 
and evaluation of interventions, and is particularly important for Southern Africa. With 
increasing access to antiretroviral therapy in Southern Africa, the rapid and cost effective 
measurements of HIV incidence are critical for the success of public health interventions. 
 
The research included in the thesis was conducted in the country with one of the highest HIV 
prevalence in the world, in a predominantly HIV-1 subtype C epidemic [1, 4]. Despite the 
burden of severe HIV-1C epidemic, Botswana has led one of the strongest responses to the 
HIV epidemic, being the first African country to offer its qualifying citizens with free 
antiretroviral drugs, care and laboratory monitoring.  
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The following topics were investigated: 
a) Evaluation of the long-term specificity (false recent classification rates) of serological 
tests for recent HIV infection, and algorithms for estimating HIV-1C incidence 
utilizing samples from patients with known long-standing HIV infection. 
b) Application of within-host viral diversity for estimation of HIV-1C recency in 
Botswana using samples collected from patients with known time since 
seroconversion in the primary HIV-1C infection cohort. 
c) Investigation of intra-host viral pairwise diversity and the time to the most common 
recent ancestor (tMRCA), as potential markers for HIV infection recency. 
 
 
Characterisation of Serological Tests for Recency of HIV Infection 
In the review paper [5] we detailed the immense progress that has been made in the 
development of biomarkers for HIV recency estimation.  These methods have become a 
reasonable alternative to the longitudinal approach for rapid assessment of interventions and 
in surveillance studies. However, serological biomarkers are sensitive to the variability in 
immune responses modulated by HIV-1 subtypes, viral load and antiretroviral therapy, 
resulting in low specificity. Implementing algorithms that include viral load, ART status and 
CD4 can reduce false recency rates [6].  We demonstrated that applying an algorithm 
including documented ART status resulted in the, to our knowledge, lowest false recent rate 
of the Limiting Antigen Avidity Assay (LAg) of 0.4% in Botswana. However, this algorithm 
is limited if ART status is unknown or self-reported. It has become feasible to test for 
presence of ARV drugs traces to verify use of ART [7]. However, this is costly and not yet 
widely available. Many countries are going to implement universal test and treat strategies, or 
general early access to treatment regardless of CD4 status. This means that the serological 
incidence assays affected by exposure to ARVs may become less useful in identifying recent 
infections. There is therefore an urgent need for new biomarkers that are less sensitive to 
ARV use. 
 
Application of within-host viral diversity for estimation of HIV-1C recency 
Viral diversity-based methods are becoming an attractive alternative to serological methods. 
These methods take advantage of the linear nature of the viral diversification over time [8-
10]. Using samples from individuals with known time since HIV infection, we demonstrated 
that pairwise diversity is significantly correlated with time since infection and can accurately 
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discriminate between recent and long-standing infection. We also found that presence of 
multiple founder strains affects the performance of the pairwise diversity assay and 
developed a method to characterise multiplicity of infection.  We also demonstrated that a 
combination of serological and molecular methods not only improves the performance of 
these methods but also provides a potentially cost-effective and practical alternative for large 
population surveys.  
 
Estimating dates of HIV infection is important for HIV incidence estimates and also for 
understanding the viral dynamics during early infection. These dates are often not known due 
to the long latency period of HIV and the lack of frequent HIV testing, while establishing 
primary infection cohorts is challenging and costly. We asked the research question whether 
we could estimate the time since infection using within-host pairwise viral diversity and time 
to the most common recent ancestor inferred from a pool of viral quasispecies. To our 
knowledge this was the first application of tMRCA for HIV recency determination in a 
heterosexual HIV-1C epidemic compared to one previous application in HIV-1 subtype B-
infected men who have sex with men (MSM) and injection drug users.  We found that 
pairwise distances and tMRCA were significantly associated with the estimated time since 
HIV infection and taking into account multiplicity of HIV infection can further strengthen 
these associations. This means that HIV-1C env-based pairwise distances and tMRCA can be 
used as potential markers for HIV recency and can help resolve instances of multiple founder 
viruses, providing a critical impact on the specificity of the serological assays and other 
simple measures of diversity.  
 
Application of cross-sectional methods in community based surveys 
Cross-sectional incidence testing is becoming a critical part of designing and calculating 
needed sample sizes in prevention studies. Some publications included in this thesis provided 
a good baseline for implementation in ongoing studies [11]. Using a cross-sectional sampling 
approach, HIV incidence was estimated at the baseline of the Botswana Combination 
Prevention Project (BCPP) in 30 rural communities from Nov 2013 to Nov 2015. The 
algorithm for estimation of HIV recency combined Limiting-Antigen Avidity Assay (LAg) 
data, ART status and HIV-1 RNA load. This study confirmed modelling estimates that 
suggest that the incidence rate in Botswana is between 1.1 and 1.4% in the past 2 years [1, 
12, 13].  Given the high level of ART scale-up [11, 14] in Botswana, studies able to identify 
HIV transmission sources and reduce HIV incidence are warranted. 
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Overall limitations of the work 
There are several limitations to this work. The publications on characterisation of serological 
assays were based on cohorts sampled mostly in the capital city of Botswana and surrounding 
villages. It would be desirable to have a wider geographical representation of sampling. 
However, Gaborone is the economic capital of Botswana and has a wide representation of 
people from different regions. Increasing specificity of the serological assays requires viral 
load testing and possible ARV drug tracing that may not be available in many resource 
settings. It is envisaged that with the widespread implementation of test and treat, the 
UNAIDS 90-90-90 targets, viral load will become more available even in low- to medium-
income countries. The application of viral diversity and tMRCA requires single-genome 
amplification and direct sequencing, which is expensive and labor intensive. The advent of 
high-throughput sequencing platforms is likely to drive the costs down. As we demonstrated, 
pairwise diversity could be used as a complementary or confirmatory assay to the serological 
methods in multi-assay algorithms. 
 
Conclusion 
Cross-sectional estimation of HIV incidence is practical and feasible using a combination set 
of serological and molecular methods.  Specificity of the methods can be improved with use 
of algorithms that include at least HIV-1 RNA load as described in the thesis publications. 
Pairwise diversity and tMRCA are promising new tools to refine HIV recency estimation. In 
addition, the usage of phylogenetic methods to characterise and better understand HIV 
transmission dynamics is essential for elimination of new HIV infections.  Applying these 
methods in a heterosexually transmitted HIV-1C epidemic in Botswana allowed us to identify 
sub-epidemics [15] and also estimate population-level HIV incidence estimates [1]. 
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CHAPTER 7 
ADDITIONAL MATERIALS 
 
The following materials will be attached as appendices 
 
 
6.1 List of Conference Abstracts related to the thematic areas 
1. Conference on Retrovirus and Opportunistic Infections (CROI 2016) 
Moyo, S et al., Cross-sectional HIV Incidence in 24 communities in Botswana. 
(Poster) 
2. 21st International AIDS Society Conference (IAS July, AIDS2016) 
Moyo, S et al., Cross-sectional estimates of HIV incidence remain high in rural 
communities in Botswana in the era of successful scale-up of ART. (Oral Poster) 
3. Viral Evolution and Molecular Epidemiology (VEME, Aug 2016) 
Moyo, S et al., Pairwise Diversity and tMRCA as potential markers for HIV Infection 
Recency. (Accepted, Poster) 
4. HIV Dynamics and Evolution (April 2016) 
Moyo, S et al., Analysis of viral diversity in relation to the recency of HIV-1C 
infection in Botswana. (Accepted Poster) 
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Abstract
Background
Cross-sectional, biomarker methods to determine HIV infection recency present a promis-
ing and cost-effective alternative to the repeated testing of uninfected individuals. We evalu-
ate a viral-based assay that uses a measure of pairwise distances (PwD) to identify HIV
infection recency, and compare its performance with two serologic incidence assays, BED
and LAg. In addition, we assess whether combination BED plus PwD or LAg plus PwD
screening can improve predictive accuracy by reducing the likelihood of a false-recent
result.
Methods
The data comes from 854 time-points and 42 participants enrolled in a primary HIV-1C
infection study in Botswana. Time points after treatment initiation or with evidence of multi-
plicity of infection were excluded from the final analysis. PwD was calculated from quasispe-
cies generated using single genome amplification and sequencing. We evaluated the ability
of PwD to correctly classify HIV infection recency within <130, <180 and <360 days post-
seroconversion using Receiver Operator Characteristics (ROC) methods. Following a sec-
ondary PwD screening, we quantified the reduction in the relative false-recency rate (rFRR)
of the BED and LAg assays while maintaining a sensitivity of either 75, 80, 85 or 90%.
Results
The final analytic sample consisted of 758 time-points from 40 participants. The PwD assay
was more accurate in classifying infection recency for the 130 and 180-day cut-offs when
compared with the recommended LAg and BED thresholds. A higher AUC statistic
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confirmed the superior predictive performance of the PwD assay for the three cut-offs.
When used for combination screening, the PwD assay reduced the rFRR of the LAg assay
by 52% and the BED assay by 57.8% while maintaining a 90% sensitivity for the 130 and
180-day cut-offs respectively.
Conclusion
PwD can accurately determine HIV infection recency. A secondary PwD screening reduces
misclassification and increases the accuracy of serologic-based assays.
1.0 Background
Identification of HIV infection recency is crucial for the accurate estimation of HIV incidence,
the evaluation of the effectiveness of antiretroviral treatment (ART) programs, and the timely
linking of HIV-infected individuals (and their partners) to treatment and care services [1–9].
The timing of infection can also be used to identify the immunological and virological charac-
teristics of individuals who have recently acquired HIV and to characterize individuals who are
putative transmitters in linked infections [10–14].
The longitudinal cohort design is currently recognized as the standard approach to identify
new HIV infections [15–17]. However, frequent HIV testing at the population level is a logisti-
cally challenging, time-consuming, and expensive enterprise. For these reasons, large-scale sur-
veillance programs are typically undertaken on a periodic basis of 12 or more months, making
it difficult to ascertain the precise date of an HIV infection. Factors associated with illness,
work commitments, temporary or cyclical migration, assumed knowledge of current HIV sta-
tus, and the stigma associated with a positive status, among others, may decrease the frequency
at which an eligible individual is captured for HIV testing [18–20]. On the other hand, the
identification of new HIV infections is possible for experimental trials where relatively small
cohorts (typically<500 individuals) are routinely tested on a weekly or monthly basis [21–23].
There is growing scientific interest in the use of cross-sectional sampling methods to iden-
tify individuals recently infected with HIV. Cross-sectional methods can mitigate the impact of
infrequent testing and the high lost-to-follow-up rates that are associated with the longitudinal
approach [24–28]. Biomarker data collected from cross-sectional sampling has also shown
great promise in the ability to differentiate between recent and established HIV infections.
Serological assays, for example, the Calypte Incidence Assay (BED) and Limiting Antigen assay
(LAg), depend on the markers of evolution of the host immune response to HIV, such as anti-
body levels, avidity, isotype and proportion [29–35]. Attention is now turning to the improve-
ment of assay-based methods and the use of multi-assay algorithms (MAA) to better predict
HIV infection recency [36].
One area that is receiving increasing attention is the use of a viral diversity measure [11, 13,
37–41]. The majority of HIV infections are caused by the transmission of a single founder
virus, resulting in a relatively homogeneous population of viral quasispecies during the early
stage of HIV infection [42–45]. Due to the error prone nature of the Reverse Transcriptase
(RT) enzyme and the host immune response to pressure, the virus is able to diversify rapidly
over time. The approximately linear diversification of HIV in early infection [46] provides a
rationale for using viral diversity as a marker for HIV infection recency [11, 39, 47, 48]. One
example of a time-dependent, viral-based diversity measure is the pairwise nucleotide diversity
(PwD). PwD measures the average number of pairwise nucleotide differences per site in DNA
Viral Diversity and Recency of HIV-1C Infection in Botswana
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sequences [11, 37, 38, 43, 49, 50]. Assays based on a measure of PwD should be less sensitive to
the variability in immune responses modulated by HIV clade, host genetics and routes of trans-
mission. However, viral-based assays are more challenging and costly to implement.
About 20–25% of HIV infections are caused by the transmission of multiple viral variants
[43, 51–53]. The rate of HIV-1 super-infection could be comparable with the rate of primary
HIV-1 infection [54], although super-infection is less frequent in the HIV-1C epidemic in
South Africa [55]. Ignoring multiplicity of HIV infection could mislead analysis and lead to
erroneous conclusions due to increased intra-host diversity in cases with multiple transmitted
HIV variants, or in super-infection. Using intra-host viral sequences that represent HIV qua-
sispecies provides an opportunity to identify phylogenetically distinct viral lineages and take
into account multiplicity of HIV infection.
In this paper, we use data from a frequently tested longitudinal HIV-1C infection cohort
(the “Tshedimoso” study from Botswana) for which the exact date of infection is known. We
assess the accuracy of the PwD assay to correctly classify HIV infection recency, and compare
its performance with the BED and LAg assays. Because of the high cost currently associated
with single genome sequencing, we further investigate the use of a MAA (BED plus PwD or
LAg plus PwD) to increase accuracy and maintain affordability. We also evaluate the addition
of viral load (VL) as a covariate to the MAA algorithm. We discuss the potential of cross-sec-
tional, biomarker information and the use of MAAs as an affordable and accurate alternative
to the longitudinal cohort approach.
2.0 Methods
2.1 Participants and specimens
The data comes from 854 time points and 42 study participants enrolled into a primary HIV-1
subtype C infection longitudinal cohort in Botswana (the “Tshedimoso” study) from April
2004 to April 2008 [56, 57]. Recent HIV-1 infections were identified by a positive HIV-1 RNA
test combined with a negative HIV-1 serology in double enzyme immunoassay [58] or by
applying a 2-step testing algorithm using the Vironostika HIV-1 Plus O Microelisa System
(bioMérieux, Durham, NC) [59]. Acutely infected participants had weekly visits for the first 2
months, biweekly visits for the next 2 months and monthly visits for the first year following the
date of seroconversion. Participants were then followed-up on a quarterly basis after the first
post-seroconversion year. The study design and participant characteristics are described in
greater detail elsewhere [56, 59, 60]. This study was conducted according to the principles
expressed in the Declaration of Helsinki. The study was approved by the Institutional Review
Boards of Botswana and the Harvard School of Public Health. All patients provided written
informed consent for the collection of samples and subsequent analysis.
2.2 Serological assays and HIV pairwise diversity for recency
determination
Blood specimens from 42 participants were used to generate 594 BED (Calypte Aware BED
HIV-1 Incidence Test, Calypte Biomedical Corporation; Portland, USA) and 597 LAg (Limit-
ing Antigen Assay, Sedia BioSciences; Portland, USA) test results according to manufacturers’
instructions [34, 35]. All available specimens were included for testing with both serological
assays. UNAIDS/WHO guidelines for determining infection recency recommend the removal
of specimens with evidence of ART use [33, 61, 62], resulting in the exclusion of 49 time points
and one participant from our analysis (see S1 Fig of the Supplement).
Viral Diversity and Recency of HIV-1C Infection in Botswana
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The intra-host viral sequences representing HIV-1C quasispecies were generated by single
genome amplification and sequencing, as described elsewhere [47, 63]. The primary goal of
sequencing was analysis of viral diversity and evolution during primary HIV-1C infection [47,
63]. The quarterly time points spanning the period from the earliest sample at enrollment to
about 500 days post seroconversion were selected from the available sampling points (S4 Fig).
Individuals with acute HIV-1C infection were sampled more frequently than individuals
enrolled during Fiebig stages IV-V [64].
The targeted region spanned HIV-1C env gp120 V1C5 corresponding to nucleotide posi-
tions 6,615 to 7,757 of HXB2. A total of 2,540 single genome amplification sequences were gen-
erated from an average of 6 time points per patient and an average of 10 multiple-sequences
(quasispecies) per time point. Both viral RNA and proviral DNA were used as templates for
amplification and sequencing. Viral sequences were codon-aligned by muscle [65] in MEGA
6.06 [66]. Mean pairwise distances (PwD) were estimated per participant per time point using
the Maximum Composite Likelihood model and pairwise deletion of gaps in MEGA 6.06 [66].
The accession numbers of the viral sequences used in this study are KC628761—KC630726.
2.3 Multiplicity of HIV infection
Previous research has shown that multiplicity of infection can result in highly variable PwD
values [33, 61, 62]. For this reason, we undertook a phylogenetic analysis to identify and
exclude time points with multiple founder variants or potential super-infection. Multiplicity
was determined by the branching topology of viral quasispecies (~1,200 bp V1C5 region of
HIV-1 env gp120) derived from a single time point of sampling. A total of 2,540 viral sequences
from 42 subjects were analyzed with 1322 HIV-1 subtype C V1C5 sequences retrieved from
the Los Alamos National Laboratory (LANL) HIV Database (S2 Table). Phylogenetic trees
were inferred by the Maximum-Likelihood (ML) using Fasttree v.2.1.8 with a GTR model of
nucleotide substitution [67]. Phylogenetic trees were visualized and inspected in FigTree [68].
Monophyletic clustering was interpreted as HIV transmission from a single source including
transmission of multiple viral variants from the same source. We excluded 47 time points and
one participant with viral quasispecies separated by reference sequence(s), as these were inter-
preted as HIV transmissions from multiple sources (including potential super-infection). The
final sample size was 758 time-points from 40 participants (see S1 Fig of the Supplement).
2.4 Statistical Analysis
We used a receiver operating characteristics (ROC) analysis to compare the accuracy of the
BED, LAg and PwD assays to identify HIV infection recency. Frequent and repeated testing of
study participants enabled us to identify the known instances of a recent HIV infection. Specifi-
cally, known HIV infection recency was defined as any specimen obtained within a<130,
<180 or<360-day post-seroconversion period. For each BED, LAg and PwD assay, we then
classified a specimen as a “recent” infection if it was below a threshold value, or classified the
specimen as an “established” infection if it was above this threshold. We refer to these as the
classified instances of a recent HIV infection [69]. For example, we classified specimens with a
BED value0.8 as a recent infection or an established infection otherwise. The recommended
threshold values for the BED and LAg assays are 0.8 and 1.5 respectively [34, 70].
The best performing thresholds for the PwD assay have yet to be definitively established.
Previous research has suggested that the rate of increase in the pairwise sequence diversity of
the HIV-1 env gene region is a constant rate of approximately 0.01 per year during early infec-
tion [46]. We therefore used these biological guidelines to select PwD thresholds of 0.004,
0.005 and 0.01 for the 130, 180 and 360-day cut-offs respectively. For each threshold, we
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obtained the sensitivity (recent infections correctly identified) and the specificity (established
infections correctly identified) using maximum likelihood estimates from a logistic regression
analysis. Because repeated measurements were taken for each participant over time, we calcu-
lated the standard errors and 95% confidence intervals (CI) for these estimates using the
Huber-White sandwich estimator [71, 72]. Given the evaluation of multiple test thresholds, we
used the highest percentage of specimens correctly classified (CC) as a guide to evaluate the
performance of each PwD threshold. The CC is computed as the sum of the recent and estab-
lished specimens correctly classified divided by the total number of specimens classified.
We next evaluated the predictive performance of combination BED plus PwD screening to
determine infection recency, and repeated this procedure for combination LAg plus PwD
screening. Specifically, our aim was to determine whether the more affordable BED or LAg
assay can be combined with the more sensitive PwD assay to reduce the likelihood of a false-
recent classification. We first screened for recent infections using a recommended BED thresh-
old of 0.8 for the 180-day cut-off and a recommended LAg threshold of 1.5 for the 130-day
cut-off. The threshold and cut-off combination selected for the analysis are based on the work
of Kassanjee et al. and Duong et al. [33–35]. We then used the PwD assay with a threshold of
0.005 to reduce the false-recency rate associated with the primary BED and LAg screening
assays. Shaw et al. [73] propose to obtain the relative true-recent rate (rTRR) and the relative
false-recent rate (rFRR) of the combined BED (or LAg) and PwD assays with:
rTRR ¼ PðBED ¼ þ; PWD ¼ þj RÞ
PðBED ¼ þjRÞ and
rFRR ¼ PðBED ¼ þ; PWD ¼ þj
RÞ
PðBED ¼ þjRÞ :
In the above equations, BED+ and PwD+ are the specimens classified as recent infections by
the respective assay, R denotes the specimens known to be recent infections and R denotes the
specimens known to be established infections. When considering the use of a second marker to
improve predictive performance, it is expected that a high rTRR (sensitivity) is maintained
while the rFRR is reduced, such that the rTRR will be close to 1.0 and the rFRR will be substan-
tially less than 1.0 [73]. We evaluate the percentage reduction in the rFRR by the PwD assay at
rTRR (sensitivity) levels of 75%, 80%, 85% and 90%. Further, we show how the addition of
viral load (VL) information can improve accuracy. Research has shown that VL measurements
<1,000 copies/mL are associated with false-recent infections and can identify individuals with
viral suppression [74, 75]. We used the methods of Shaw et al. [73], Janes et al. [76] and Pepe
et al. [77] to obtain estimates for the rFRR and its 95% conﬁdence intervals. Statistical analyses
were undertaken in Stata 13.1.
The mean duration of recent infection (MDRI), the average time being recent while infected
for less than time cut-off time (T) was estimated using the Incidence Estimation Tools version
1.0.5.9001 (The inctools package in R software version 3.2.4). The T value of 2 years and time
points with viral load above 1,000 copies/mL were used for the MDRI calculation.
3.0 Results
All of the 2,540 sequences from the 42 participants in the cohort were classified as subtype C.
To account for multiplicity of HIV infection and avoid inflated estimate of HIV pairwise dis-
tances, time points with phylogenetically distinct viral lineages (n = 47) were excluded from
analysis (see section 2.3 Multiplicity of HIV infection in Methods). The final analytic sample
consisted of 758 (BED = 554, LAg = 579, and PwD = 238) time-points from 40 participants
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(see S1 Fig of the Supplement for the data flow diagram). Among the study participants, 28
(70%) were female. The median (IQR) age at enrollment was 27 (20–56) years. Participants
were followed for a median (IQR) of 45.9 (32.4–53.9) months, with a median (IQR) of 21 (18–
27) time points per participant. The mean (SD) and median (IQR) time between tests were 2.0
(±2.9) months and 1.1 (0.92–3.0) months respectively. Table 1 shows the summary statistics
for the participant characteristics and covariate measures.
We present the maximum likelihood estimates for the PwD assay in S1 Table of the supple-
ment. Given that there is currently no recommended PwD threshold, we show the sensitivity
and specificity estimates for values ranging from 0.0005 to 0.015. For the 130-day cut-off, a
PwD threshold of 0.004 gives a sensitivity of 76.2% and a specificity of 79.7%, with 77.8% of the
total specimens correctly classified. For the 180-day cut-off, a PwD threshold of 0.005 gives a
sensitivity of 74.5% and a specificity of 75.5%, with 74.9% of the total specimens correctly clas-
sified. We found that PwD values of 0.0055 and 0.006 performed slightly better than the 0.004
and 0.005 values for both the 130 and 180-day cut-offs, and are biologically plausible given that
HIV is known to evolve at a rate of approximately 0.01 per year.
We found the PwD threshold values (reported above) to be more accurate than the recom-
mended LAg = 1.5 and BED = 0.8 threshold values in identifying infection recency. For a
130-day cut-off and a threshold value of 1.5, the LAg assay gives a sensitivity of 71.3% and a
specificity of 72.9%, with 72.4% of the total specimens correctly classified. For a 180-day cut-
off and a threshold value of 0.8, the BED assay gives a sensitivity of 87.4% and a specificity of
50.2%, with 65.5% of the total specimens correctly classified. For these cut-offs and thresholds,
we see that the PwD assay has a higher proportion of specimens correctly classified when com-
pared with the LAg and BED assays.
We also compare the accuracy of the three assays to identify infection recency using the
AUC estimate of a ROC graph. An AUC closer to 1.0 indicates a better accuracy, and we show
these estimates along with their standard errors and 95% CIs in Table 2. The AUC value for the
130-day cut-off is 0.83 compared with 0.78 for the BED assay and 0.81 for the LAg assay. For
the 180-day cut-off, these values are PwD = 0.82, BED = 0.75, and LAg = 0.79 and for the
360-day cut-off these are PwD = 0.78, BED = 0.74, and LAg = 0.72 (see also Fig 1).
We investigated whether MAA could further distinguish recent from established infections.
Table 3 shows the ability of the PwD assay to improve predictive accuracy by reducing the rela-
tive false-recent rate (rFRR) of the LAg and BED assays. Here, we are specifically interested in
the percentage reduction in the rFRR and so we subtract the rFRR estimate from 100%. As an
example, we interpret the result for the LAg plus PwD combination screening for the 130-day
Table 1. Participant and covariate characteristics.
Participant Characteristics n = 40
Female, N (%) 28 (70)
Age (years), Median (IQR) 27 (20–56)
Time under observation (months), Median (IQR) 45.9 (32.4–53.9)
Difference between time points (months), Median (IQR) 1.1 (0.92–3.0)
Total time points per participant, Median (IQR) 21 (18–27)
Assay time points per participant, Median (IQR)
BED 14 (10–19)
Lag 14.5 (7–22)
PwD 5 (4–6)
CD4 cells/μl, Median (IQR) 417 (302–569)
Viral load (log10) copies/mL, Median (IQR) 3.9 (2.65–4.73)
doi:10.1371/journal.pone.0160649.t001
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cut-off as follows: The PwD assay reduces the rFRR by (100–48) 52% while maintaining a 90%
rTRR (sensitivity) of the LAg assay. We can also interpret this result using the upper bound of
the 95% CI: the PwD assay reduces the rFRR by at least (100–87.5) 12.5% while maintaining a
LAG sensitivity of 90%.
Results show that the PwD assay reduces the rFRR by (100–42.2) 57.8%, or that it reduces
the rFRR by at least (100–62.8) 37.2%, while maintaining a 90% sensitivity of the BED assay.
Panel D of S2 Fig provides a graphical illustration of the reduction in the rFRR due to the BED
plus PwD combination screening. The panel shows the rFRR estimate (red dot) on the ROC
graph that corresponds with a 90% sensitivity (y-axis) and a 42.2% false-recent (x-axis) value.
The red bar represents the 95% CI of the rFRR. Panels A-C of S2 Fig show that rFRR estimates
at a sensitivity levels of 75%, 80% or 85% respectively, the values of which can be obtained
from Table 3.
We further provide a data flow diagram in S3 Fig to demonstrate the procedure used to pro-
duce the results for Table 3. There were 217 time points that had values for both the PwD and
BED assays, of which 134 were known to be recent. We first used a recommended BED thresh-
old of0.8 to classify 168 time points as recent infections. We then used a PwD threshold of
0.005 to re-screen these 168 time points in order to improve predictive accuracy. S3 Fig
shows a reduction in the number of false-recent infections from 45 to 16 (64%) due to the PwD
screening, while maintaining a BED sensitivity of 91.6%. This result differs slightly from that of
Table 3, which is interpreted at an exact sensitivity of 90%.
We then show how additional biomarker information can be used to improve the combina-
tion screening procedure. Here we hypothesize that treatment naïve participants with viral
loads<1000 copies/mL are less likely to be recently infected with HIV. Fig 2 shows the BED
plus PwD screening for the 180-day cut-off. The rFRR estimate is 31.6% (95% CI: 11.0–63.1),
which shows that the PwD assay and VL information reduces rFRR by 68.4% (or by at least
36.9%) while maintaining a BED sensitivity of 90%. We also show this result for the LAg plus
PwD combination screening for the 130-day cut-off in Fig 3.
Table 2. Area under the curve (AUC) of a receiver-operator characteristics (ROC) graph comparing
the accuracy of the PwD, BED, and LAg assays in identifying HIV infection recency.
Assay AUC SE 95% CI
130-day cut-off
PWD 0.83 0.03 0.78–0.88
BED 0.78 0.02 0.74–0.82
LAg 0.81 0.02 0.78–0.85
180-day cut-off
PWD 0.82 0.03 0.76–0.88
BED 0.75 0.02 0.71–0.79
LAg 0.79 0.02 0.75–0.82
360-day cut-off
PWD 0.78 0.05 0.68–0.89
BED 0.74 0.03 0.69–0.79
LAg 0.72 0.02 0.68–0.77
The table shows the results for the area under the curve (AUC) of a receiver operating characteristics (ROC)
graph. The AUC is an objective measure of the accuracy of a classiﬁcation schema. The best possible value
is 1.0, which represents a 100% sensitivity and 100% speciﬁcity of the assay to correctly distinguish recent
from established HIV infections. The results show that the PwD assay has the best predictive performance
for the three window periods. CI: conﬁdence interval.
doi:10.1371/journal.pone.0160649.t002
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Finally, we estimated MDRI’s for PwD using a threshold of 0.005, BED and LAg using stan-
dard thresholds of 0.8 and 1.5 respectively. PwD had an estimated MDRI of 128 days (95% CI
92–185). BED and LAg had estimated MDRIs of 267 days (95% 212–335) and 129 days (81–
190), respectively (S4 Table)
4.0 Discussion and Conclusion
There is an urgent need in HIV research to classify infection recency using accurate, practical
and cost effective methods [29, 78–81]. In this study, we evaluate the accuracy of a viral-based
assay, HIV pairwise diversity (PwD), to identify participants recently infected with HIV. Our
study provides information on the best-performing thresholds for the PwD assay, and com-
pares this assay with two serologic-based assays, BED and LAg. We found that PwD threshold
values in the range of 0.005 and 0.006 gave a high sensitivity and specificity for the 130 and
Fig 1. ROC graphs comparing the predictive performance of the PwD, LAg and BED assays for determing HIV infection recency for the
130, 180, and 360-day cut-offs.We used the area under the curve (AUC) of a receiver operator characteristics (ROC) graph to assess the
accuracy of the PwD, BED and Lag assays to identify HIV infection recency. The best possible AUC value is 1.0. The ROC graphs are produced
by calculating the sensitivity and specificity at different thresholds, which are typically incremented by a fixed value over the minimum and
maximum range of the assay. The AUC results show that the PwD assay is the most accurate identifier of infection recency for the three cut-off
periods.
doi:10.1371/journal.pone.0160649.g001
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180-day cut-offs. These values are biologically feasible and consistent with previous work. For
example, studies have determined that the mean pairwise sequence diversity of the HIV-1 env
gene region increases at an approximately constant rate of 0.01 per year during early HIV
infection [46]. Other studies using a different measure of HIV diversity, namely proportion of
ambiguous sites, found that a threshold ranging from 0.0045 to 0.005 gave a high sensitivity for
the 180-day cut-off [11]. Xia et. al. [82] show that a 0.006 diversity cut-off distinguished recent
infections with both single and multiple infections.
The results of our study show that the PwD assay can accurately identify recent HIV infec-
tions. The PwD assay gave the best performance for the 130, 180, 360-day cut-offs according to
the AUC estimates. PwD thresholds of 0.004 and 0.005 correctly classified a higher proportion
of specimens when compared with BED and LAg thresholds of 0.8 and 1.5 respectively. We
also evaluated a multi-assay algorithm (BED plus PwD or LAg plus PwD) to identify HIV
infection recency. Our algorithm first uses an affordable, serologic based assay (BED or LAg)
to identify a high proportion of true-recent HIV infections, and then the more sensitive PwD
assay to reduce the percentage of specimens misclassified as recent infections. Combination
screening significantly improved the classification of HIV infection recency. We found that the
PwD assay was able to reduce the relative false-recency rate (rFRR) by approximately 52%
while maintaining a LAg sensitivity of 90% for the 130-day cut-off. PwD reduced the rFRR by
approximately 58% while maintaining a BED sensitivity of 90% for the 180-day cut-off. Results
also show an improvement in accuracy when including biomarker information such as partici-
pant viral load (VL).
Table 3. Combination assay screening to identify HIV infection recency for the 130 and 180-day cut-offs periods.
Sensitivity level Relative False- Recency Rate 95% Lower bound 95% Upper bound
BED+PwD 75 28.3 13.8 47.9
130-day 80 35.0 17.0 48.3
cut-off 85 36.7 19.4 52.1
90 40.0 23.2 68.5
BED+PwD 75 28.9 11.8 44.6
180-day 80 31.1 13.8 46.2
cut-off 85 31.1 18.1 53.2
90 42.2 21.1 62.8
LAg+PwD 75 44.0 25.0 68.2
130-day 80 48.0 28.6 68.4
cut-off 85 48.0 27.5 73.3
90 48.0 30.9 87.5
LAg+PwD 75 42.1 15.8 71.8
180-day 80 42.1 17.4 73.3
cut-off 85 42.1 18.5 71.8
90 47.4 22.2 83.3
The table shows the reduction in the relative false-recency rate (rFRR) of the BED and LAg assays due to the PwD assay. A BED = 0.8 or LAg = 1.5
threshold was ﬁrst used to screen the specimens for HIV infection recency. Specimens classiﬁed as recent were then re-screened using the PwD assay in
order to reduce the rFRR while maintaining a 75%, 80%, 85% or 90% true-recency rate (sensitivity) of the BED or LAg assay. Since we are interested in the
reduction of the rFRR by the PwD assay, we subtract this estimate from 100%. The results can be interpreted as follows: for the 180-day cut-off, the PwD
assay reduces the rFRR by (100–42.2 =) 57.8% while maintaining a BED sensitivity of 90%. The table also gives the 95% conﬁdence bounds for the
reduction in the rFRR. The same result can be interpreted as follows: for the 180-day cut-off, the PwD assay reduces the rFRR by at least (100–62.8 =)
37.2% while maintaining a BED sensitivity of 90%.
doi:10.1371/journal.pone.0160649.t003
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Prior research has shown that the presence or active use of ART can reduce HIV diversity
and result in the misclassification of infection recency [62, 83]. The sensitivity of incidence
assays can be maintained if auxiliary patient information on ART usage is collected at the same
time as the blood specimen. The collection of additional information, such as VL or CD4
counts, has also been shown to improve the performance of bio-marker based assays to detect
infection recency [12, 13, 32]. Our study confirms that the inclusion of VL as a covariate in the
analysis significantly reduced the false-recent rate of the BED or LAg assays while maintaining
a high sensitivity [12, 84, 85]. Collecting VL or CD4 count information may however increase
Fig 2. Shows a reduction in the relative false-recency rate (rFRR) when viral load information is added to
the combination BED plus PwD screening procedure. The figure shows how additional biomarker information
can be used to improve the combination screening procedure for the 180-day cut-off. We hypothesize that
treatment naïve participants with viral loads1000 copies/mL are more likely to be recently infected with HIV.
Results show an rFRR estimate of 31.6% (95% CI: 11–63.1) at a 90% sensitivity level. Since we are interested in
the reduction of the rFRR by the PwD assay, we subtract this estimate from 100%. Thus, the PwD assay reduces
the rFRR by 68.4% (or by at least 36.9% given the upper bound of the 95% CI) while maintaining a BED sensitivity
of 90% for the subsample of VL >1000 copies/mL specimens. The figure displays both ROC curves for the viral
load covariate and the corresponding rFRR estimates (displayed by the dotted vertical lines).
doi:10.1371/journal.pone.0160649.g002
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operational costs. Some of these markers may not be readily available during routine cross-sec-
tional surveys or for previously collected specimens. The PwDMDRI estimates are similar to
LAg MDRI recently published [34, 86], although larger sample sets could help to evaluate dif-
ferent thresholds of PwD.
In this paper, we excluded time points with evidence of multiple founder variants or super-
infection. Previous research has shown that multiplicity of infection can result in highly vari-
able pairwise distances. PwD values calculated from multi-infection time points are likely to
fall outside of the expected range, and do not give an accurate estimate of HIV diversity [61,
87]. Methods to better identify multi-infections in cross sectional sampling are currently being
Fig 3. Shows a reduction in the relative false-recency rate when viral load information is added to the
combination LAg plus PwD screening. The figure shows how additional biomarker information can be used to
improve the combination screening procedure for the 130-day cut-off. We hypothesize that treatment naïve
participants with viral loads1000 copies/mL are more likely to be recently infected with HIV. Results show an
rFRR estimate of 38.1% (95% CI: 15.8–88.6) at a 90% sensitivity level. Since we are interested in the reduction of
the rFRR by the PwD assay, we subtract this estimate from 100%. Thus, the PwD assay reduces the rFRR by
61.9% (or by at least 11.4% given an upper bound of the 95% CI) while maintaining a LAg sensitivity of 90% for the
subsample of VL <1000 copies/mL specimens. The figure displays both ROC curves for the viral load covariate and
the corresponding rFRR estimates (displayed by the dotted vertical lines).
doi:10.1371/journal.pone.0160649.g003
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developed. The PwD assay may be of limited use in men who have sex with men (MSM) [88,
89] due to a high multiplicity of infection. However, more than 80% of all heterosexual HIV
infections are seeded by a single founder strain [42–45], which is the main route of transmis-
sion in Botswana.
One current limitation associated with the wide-scale use of the PwD assay is the cost of
genomic sequencing, which requires expensive laboratory equipment, the training of staff and
the technically demanding task of generating single genomes or clonal sequences. The current
cost of generating quasispecies from a single time point ranges from $150–200$ compared to
$5.29 and $2.35 per test for LAg and BED, respectively. Nevertheless, we argue that the data
generated from genome sequencing can address a range of research questions related to the
timing of infections in transmission clusters, the number of strains infecting individuals, tro-
pism of the virus and the selection of optimal drug regimens. In this regard, the costs of
genome sequencing would be absorbed into a body of research initiatives and questions, rather
than used exclusively for the generation of a viral diversity measure. It is also likely that expen-
sive viral-based assays will become a moot point in the near future as the cost of genomics tech-
nology continues to decline.
In conclusion, serologic assays and their algorithms have become increasingly popular in
recent years because they are based on antibody laboratory tests that are cheaper, quicker and
relatively straightforward to implement at the population level [30, 31, 80, 90]. In this study,
we show that a measure of HIV diversity can accurately classify infection recency. Our results
show that BED plus PwD or LAg plus PwD combination screening has the potential to cor-
rectly identify a high proportion of recent HIV infections in a cost-effective manner. The use of
bio-marker based assays and cross-sectional data to identify HIV infection recency presents a
promising alternative to the resource-intensive approach of a longitudinal cohort design. With
continued development, these assays hold the potential to accurately estimate HIV incidence,
monitor the spread of the epidemic, evaluate the impact of treatment interventions and inform
the design of vaccine and prevention trials.
Supporting Information
S1 Fig. Data flow diagram showing total time points and participants included in the final
analysis.
(PNG)
S2 Fig. ROC graphs showing a reduction in the relative false-recency rate (rFRR) of the
BED assay by the PwD assay for the<180-day cut-off. The figure gives an example of the
reduction in the relative false-recency rate (rFRR) of the BED assay by the PwD assay for the
180-day cut-off. The panels A-D show the ROC curves for the four sensitivity levels. The y-axis
is the sensitivity and the x-axis the false-recency rate (1 –specificity); the red point on each
graph is the rFRR estimate along with its 95% CI, as shown by the red error bar. The PwD
assay reduces the rFRR by 57.8% while maintaining a 90% sensitivity of the BED assay. The
ROC graphs show that after performing combination screening, an rFRR estimate can be
obtained for any sensitivity value between 0 and 1.0.
(PNG)
S3 Fig. Flow chart of the combination BED plus PwD screening to identify HIV infection
recency for the 180-day cut-off. Flow chart showing how the PwD assay can be combined
with the BED assay to reduce the likelihood of a false-recent result (i.e., established infections
misclassified as recent infections). A recommended BED assay threshold value of 0.8 was used
to classify infection recency for the N = 217 specimens. This first screening correctly identified
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123 of the 134 recent infections for the 180-day cut-off (true positives), giving a sensitivity of
91.8%. However, 45 of the 83 (54.2%) established specimens were falsely classified as recent. A
PwD threshold of 0.005 was then used to screen the subset of specimens classified as recent
(n = 168) by the BED assay. Results show that the secondary PwD screening reduces the false-
recent infections by 64% (45 to 16 specimens) at a BED sensitivity of 87.8%. (This result differs
slightly from that of Table 3, which is interpreted at an exact sensitivity of 90%.)
(PNG)
S4 Fig. Distribution of time-points for the BED, LAg and PwD assays. The figure gives the
analysed time points of sampling and sequencing in the study since the known time of serocon-
version. Time in days post-seroconversion is shown on the x-axis.
(PNG)
S5 Fig. Spaghetti plots for the BED, LAg and PwD time-points.
(PNG)
S1 Table. Performance of PwD threshold values to determine HIV Infection Recency for
130, 180, and 360-day cut-offs. The table shows the performance of the PwD threshold values
to identify HIV infection recency. The range of values were selected according to rate of
increase in the pairwise sequence diversity of the HIV-1 env gene region, which is approxi-
mately a constant rate of 0.01 per year during early infection. For example, a 180-day cut-off
corresponds with a PwD value of 0.005. We selected thresholds values in the range of these bio-
logical values for each of the cut-off periods. For each threshold we obtained the sensitivity,
specificity, their 95% CI, likelihood ratio, and percentage correctly classified. For the 130-day
cut-off, a PwD threshold of 0.005 correctly identified 79.37% (95% CI: 62.83–95.9) of the recent
infections (sensitivity) and correctly identified 72.57% (95% CI: 61.87–83.26) of the established
infections (specificity), giving a percentage correctly classified of 76.15%.
(DOCX)
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(DOCX)
S3 Table. Area under the curve (AUC) for the PwD, BED, and LAg assays for shared time-
points (n = 238). Table shows the results for the area under the curve (AUC) of a receiver
operating characteristics (ROC) graph for the<130,<180- and<360-day cut-offs. Using only
shared time-points (n = 238) significantly reduces the sample size and therefore the perfor-
mance of the three assays. The performance of the three assays are therefore indistinguishable
given the overlap in the confidence intervals of the AUC estimates.
(DOCX)
S4 Table. Mean Duration of Recent Infection for BED, LAg and PwD Assays. Table shows
the estimated Mean Duration of Recent Infection (MDRI), average time ‘recent’ while infected
for less than some time cut-off T for the BED, LAg and PwD assays.
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Background: The successful scale up of the national ART program in Botswana has almost reached the UNAIDS “90-90-90” goal (Gaolathe et al.,
CROI-2016). Cross-sectional estimate of HIV incidence needs to take into account ARV use to avoid mis-classification of HIV recency.
Methods: Using cross-sectional sampling HIV recency was estimated at the baseline of the Botswana Combination Prevention Project in 30 rural
communities from Nov 2013 to Nov 2015. The algorithm for estimation of HIV recency combined Limiting-Antigen Avidity Assay (LAg) data, ART
status and HIV-1 RNA load (as described in Rehle et al., PLoS One 2015;10:e0133255). The LAg cut-oﬀ normalized optical density was 1.5. ART
status was documented. The HIV-1 RNA cut-oﬀ was 400 cps/mL. The Mean Duration of Recent Infection was 130 days and the False Recent Rate
was zero.
Results: During the baseline household survey, a total of 3,596 individuals tested HIV positive among 12,570 individuals with definitive HIV status.
Among those testing HIV positive, 3585 (99.7%) had a research blood draw available, of whom 3580 (99.9%) had LAg data generated. Of those,
326 were identified as LAg-recent cases. Among those, 278 individuals were considered chronically infected based on their documented ART
status. Among the remaining 48 ART-naïve individuals, 14 had an HIV-1 RNA load ≤400 cps/mL. The Botswana MoH electronic medical records
system was queried for these 14, 10 were found in the MoH data and evidence for initiation of ART was found for 5 individuals. ARV-naïve status
could not be confirmed in 9 individuals. Thus, 34 LAg-recent, ARV-naïve individuals with HIV-1 RNA above 400 cps/mL were classified as
individuals with recent HIV infections. HIV incidence was estimated at 1.06% (95% CI 0.70%-1.42%). Including 9 virologically suppressed
individuals with uncertain ART status brings the estimate of HIV incidence to 1.34% (95% CI 0.91%-1.77%).
Conclusions: Using an algorithm including LAg-Avidity EIA, documented ART status and HIV-1 RNA load, cross-sectional HIV incidence in 30 rural
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HIV transmission sources and reduce HIV incidence are warranted.
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Abstract  Body::  
Direct real-time estimates of HIV incidence using cross-sectional sampling can 
provide critical information for design and evaluation of HIV prevention 
interventions. The ongoing scale-up of ART in southern African countries presents 
a substantial challenge to the accuracy and reliability of cross-sectional methods 
used for identiﬁcation of HIV recency.
HIV recency was estimated at the baseline of the Botswana Combination 
Prevention Project (BCPP). Cross-sectional data were collected during household 
surveys in 24 rural communities from Nov 2013 to Aug 2015. An HIV incidence 
testing algorithm combining the Limiting-Antigen Avidity Assay (LAg-Avidity EIA) 
with ART status and level of HIV-1 RNA load (multi-assay algorithm described in 
Rehle et al., PLoS One 2015;10:e0133255) was used. The LAg cut-oﬀ normalized 
optical density was 1.5. ART status was documented. The HIV-1 RNA cut-oﬀ was 
400 cps/mL. The Mean Duration of Recent Infection was 130 days and the False 
Recent Rate was set to zero.
A total of 2,727 individuals tested HIV-positive among 9,745 individuals with 
deﬁnitive HIV status (28.3% HIV prevalence after adjustment for study design; 95% 
CI: 25.6%–31.2%) during the baseline household surveys. About 70% of 
HIV-positive individuals were already on ART. LAg-Avidity EIA data was generated 
for 2,710 of 2,719 (99.7%) HIV-positive individuals with research blood draw 
available, and 234 cases were identiﬁed as LAg-Avidity EIA recent. Among those, 
198 individuals were considered chronically infected based on their documented 
ART status. Eleven of 36 LAg-Avidity EIA recent, ARV-naïve individuals had an HIV-1 
RNA load ≤400 cps/mL, and were classiﬁed as having long-term HIV infections. 
Thus, 25 LAg-Avidity EIA recent, ARV-naïve individuals with HIV-1 RNA above 400 
cps/mL were classiﬁed as individuals with recent HIV infections. HIV incidence 
across 24 communities was estimated at 1.00% (95% CI 0.60%–1.41%).
The increasing scale-up of ART in southern African communities requires 
adjustment of cross-sectional methods for identiﬁcation of HIV recency. An 
algorithm that combines LAg-Avidity EIA testing with ART status and HIV-1 RNA 
data was used to estimate baseline HIV recency in 24 rural communities at 
baseline of the BCPP. This algorithm should be validated by longitudinal HIV 
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adjustment of cross-sectional methods for identiﬁcation of HIV recency. An 
algorithm that combines LAg-Avidity EIA testing with ART status and HIV-1 RNA 
data was used to estimate baseline HIV recency in 24 rural communities at 
baseline of the BCPP. This algorithm should be validated by longitudinal HIV 
incidence data in the future. HIV incidence in rural communities in Botswana was 
estimated at 1.0% in 2013–2015.
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